Amanote Research
Register
Sign In
Pnd155 - Reduced Relapse Rates and Improved Quality of Life for Relapsing-Remitting Multiple Sclerosis (Rrms) Patients Treated With Natalizumab vs Injectable Therapies
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2903
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
S Naoshy
J Pike
E Jones
A Hadfield
S Licata
Publisher
Elsevier BV
Related search
Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Chemical Health
Pharmacology
Safety
Medicine
Toxicology
Safety Research
Pharmaceutics
Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life
Patient Related Outcome Measures
Comparing the Quality of Life Among Patients With Relapsing Remitting Multiple Sclerosis in Iraq Using Different Disease Modifying Therapies
Iraqi Journal of Pharmaceutical Sciences
Toxicology
Analytical Chemistry
Pharmaceutics
Pharmacology
Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis
Neuropsychiatric Disease and Treatment
Psychiatry
Mental Health
Biological Psychiatry
Health State Utilities in Patients With Relapsing Remitting Multiple Sclerosis Treated With Cladribine Tablets
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis
Arquivos de Neuro-Psiquiatria
Biological Psychiatry
Neurology
Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting
Journal of Neurology & Neurophysiology
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+T Cells of Patients With Relapsing-Remitting Multiple Sclerosis
Journal of Immunology Research
Medicine
Allergy
Immunology
